Correction to “New approaches in gene therapy for sickle cell disease, moving in vivo”

IF 7.6 2区医学 Q1 HEMATOLOGY

HemaSphere Pub Date : 2024-06-26 DOI:10.1002/hem3.107

引用次数: 0

Abstract

Kent DG. New approaches in gene therapy for sickle cell disease, moving in vivo. HemaSphere. 2024;8:e43.

In paragraph 2, the final sentence included the text “…involves large granulocyte-macrophage progenitor-level virus protection…”, which was incorrect. This should have read “Therapies that might remove the in vitro component, which involves substantial good manufacturing practice virus production and extensive quality control regimens, would therefore be of great utility and the field of in vivo therapies has understandably garnered intense interest”.

We apologize for this error.

查看原文本刊更多论文

更正 "镰状细胞病基因治疗的新方法，在体内移动"

Kent DG.体内移动的镰状细胞病基因治疗新方法。HemaSphere.在第2段中，最后一句包含"......涉及大量粒细胞-巨噬细胞祖细胞水平的病毒保护......"，这是不正确的。应改为 "体外疗法涉及大量良好生产规范的病毒生产和广泛的质量控制制度，因此，去除体外部分的疗法将大有用武之地，可以理解，体内疗法领域已引起了人们的浓厚兴趣"。我们对这一错误表示歉意。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

HemaSphere Medicine-Hematology

CiteScore

6.10

自引率

4.50%

发文量

2776

审稿时长

7 weeks

期刊介绍： HemaSphere, as a publication, is dedicated to disseminating the outcomes of profoundly pertinent basic, translational, and clinical research endeavors within the field of hematology. The journal actively seeks robust studies that unveil novel discoveries with significant ramifications for hematology. In addition to original research, HemaSphere features review articles and guideline articles that furnish lucid synopses and discussions of emerging developments, along with recommendations for patient care. Positioned as the foremost resource in hematology, HemaSphere augments its offerings with specialized sections like HemaTopics and HemaPolicy. These segments engender insightful dialogues covering a spectrum of hematology-related topics, including digestible summaries of pivotal articles, updates on new therapies, deliberations on European policy matters, and other noteworthy news items within the field. Steering the course of HemaSphere are Editor in Chief Jan Cools and Deputy Editor in Chief Claire Harrison, alongside the guidance of an esteemed Editorial Board comprising international luminaries in both research and clinical realms, each representing diverse areas of hematologic expertise.